Mikha Pablo Nathanael Sagala, Eristia Arfi, Nela Rizka
Neuroblastoma is the most common type of extracranial solid tumour in childhood. Celyvir is an immunotherapy treatment that uses mesenchymal cells (MSC) containing an oncolytic virus of the type ICOVIR 5. The purpose of this study is to examine the mathematical model of neuroblastoma treatment using celyvir in obtaining the minimum dose administered. This is done by studying two different ways of conducting treatment: continuous and periodic. In this study, the minimum dose (viral load) for the periodic model will be analysed, where this model reveals the minimum dose of celyvir to achieve remission of neuroblastoma. After obtaining the minimum dose value for the periodic model, a comparison was made to the minimum dose of the continuous model and found that both treatment models have the same treatment response when treatment has been carried out for a long period of time. Simulations were conducted to study both minimum dose models. The results showed that the minimum dose of the periodic model achieved neuroblastoma remission faster than the minimum dose of the continuous model. After varying the parameter values, the results obtained are not much different from the previous results. As the administration of celyvir is generally not continuous, the treatment of neuroblastoma can use the periodic model with the dose given in the range of 1.314×106 to 2.106×108 © 2025 Author(s).
Sumatera Institute of Technology, Lampung, Indonesia
Research at a Glance
Register to unlock
Topics & SDG Alignment
Register to unlock
Collaboration
Register to unlock
Author Profile (Selected)
Register to unlock
References Overview
Register to unlock
Journal & Source
Register to unlock
Metadata & Integrity
Register to unlock